journal
MENU ▼
Read by QxMD icon Read
search

Oncologist

journal
https://www.readbyqxmd.com/read/28808093/are-disagreements-in-caregiver-and-patient-assessment-of-patient-health-associated-with-increased-caregiver-burden-in-caregivers-of-older-adults-with-cancer
#1
Tina Hsu, Matthew Loscalzo, Rupal Ramani, Stephen Forman, Leslie Popplewell, Karen Clark, Vani Katheria, Rex Strowbridge, Redmond Rinehart, Dan Smith, Keith Matthews, Jeff Dillehunt, Tao Feng, David Smith, Canlan Sun, Arti Hurria
BACKGROUND: As patients age, caregivers increasingly provide essential support and patient information. We sought to determine if patient-caregiver assessments of patient health differ and if differences contribute to burden in caregivers of older adults with cancer. MATERIALS AND METHODS: One hundred patients, aged ≥65, and their caregivers independently assessed patient function, comorbidity, nutrition, social activity, social support, and mental health. Caregivers completed the Caregiver Strain Index (CSI)...
August 14, 2017: Oncologist
https://www.readbyqxmd.com/read/28798274/disparities-of-trastuzumab-use-in-resource-limited-or-resource-abundant-regions-and-its-survival-benefit-on-her2-positive-breast-cancer-a-real-world-study-from-china
#2
Jianbin Li, Shusen Wang, Yongsheng Wang, Xiaojia Wang, Haibo Wang, Jifeng Feng, Qingyuan Zhang, Tao Sun, Quchang Ouyang, Yongmei Yin, Yinhua Liu, Cuizhi Geng, Min Yan, Zefei Jiang
BACKGROUND: Trastuzumab is a key component of therapy for human epidermal growth receptor 2 (HER2) positive breast cancer. Because real-world data are lacking, the present research was conducted to evaluate the the actual use of and the effectiveness of trastuzumab in the real world in China. METHODS: Inpatients with HER2 positive invasive breast cancer from 13 hospitals in Eastern China (2010-2015, n = 1,139) were included in this study. We aimed to assess the actual use of trastuzumab and to evaluate potential efficacy from trastuzumab in real-world research...
August 10, 2017: Oncologist
https://www.readbyqxmd.com/read/28798273/in-reply
#3
LETTER
Khurum Khan, David Cunningham, Katharine Aitken, Sheela Rao
No abstract text is available yet for this article.
August 10, 2017: Oncologist
https://www.readbyqxmd.com/read/28798272/perspectives-of-screening-eligible-women-and-male-partners-on-benefits-of-and-barriers-to-treatment-for-precancerous-lesions-and-cervical-cancer-in-kenya
#4
Kathleen R Ragan, Natasha Buchanan Lunsford, Judith Lee Smith, Mona Saraiya, Millicent Aketch
BACKGROUND: Cervical cancer is the leading cause of female cancer mortality in Kenya. Kenya's National Cervical Cancer Prevention Program Strategic Plan outlines efforts to reduce the burden; however, treatment services remain limited. This study identified male and female perspectives regarding benefits, facilitators, and barriers to treatment for precancerous lesions and cervical cancer. MATERIALS AND METHODS: Ten focus groups were conducted in Nairobi and Nyanza in 2014 with females aged 25-49 years (n = 60) and male partners (n = 40)...
August 10, 2017: Oncologist
https://www.readbyqxmd.com/read/28798271/the-search-for-surrogate-endpoints-in-trials-in-diffuse-large-b-cell-lymphoma-the-surrogate-endpoints-for-aggressive-lymphoma-project
#5
Daniel J Sargent, Qian Shi, Christopher R Flowers, Norbert Schmitz, Thomas M Habermann, Jocelyne Flament, Tommy Fu, Bertrand Coiffier
No abstract text is available yet for this article.
August 10, 2017: Oncologist
https://www.readbyqxmd.com/read/28798270/a-phase-i-dose-escalation-study-of-the-safety-and-pharmacokinetics-of-pictilisib-in-combination-with-erlotinib-in-patients-with-advanced-solid-tumors
#6
Stephen Leong, Rebecca A Moss, Daniel W Bowles, Joseph A Ware, Jing Zhou, Jill M Spoerke, Mark R Lackner, Geetha Shankar, Jennifer L Schutzman, Ruud van der Noll, Emile E Voest, Jan H M Schellens
BACKGROUND: Epidermal growth factor receptor (EGFR) and phosphatidylinositol 3-kinase (PI3K) are involved in the proliferation and survival of many cancer types. Enhanced antitumor activity may be achieved through combined inhibition of these pathways. We report results for pictilisib (GDC-0941, a class I pan-PI3K inhibitor) plus erlotinib (an EGFR tyrosine kinase inhibitor) in patients with advanced solid tumors. MATERIALS AND METHODS: A 3 + 3 dose-escalation study was carried out at a starting daily dose of 60 mg pictilisib on days 1-21 of a 28-day cycle and 150 mg erlotinib from day 2 of cycle 1...
August 10, 2017: Oncologist
https://www.readbyqxmd.com/read/28798269/regarding-survival-outcomes-in-asymptomatic-patients-with-normal-conventional-imaging-but-raised-carcinoembryonic-antigen-levels-in-colorectal-cancer-following-positron-emission-tomography-computed-tomography-imaging
#7
LETTER
https://www.readbyqxmd.com/read/28778960/current-treatments-for-surgically-resectable-limited-stage-and-extensive-stage-small-cell-lung-cancer
#8
Thomas E Stinchcombe
The prevalence of small cell lung cancer (SCLC) has declined in the U.S. as the prevalence of tobacco use has declined. However, a significant number of people in the U.S. are current or former smokers and are at risk of developing SCLC. Routine histological or cytological evaluation can reliably make the diagnosis of SCLC, and immunohistochemistry stains (thyroid transcription factor-1, chromogranin, synaptophysin, and CD56) can be used if there is uncertainty about the diagnosis. Rarely do patients present with SCLC amendable to surgical resection, and evaluation requires a meticulous workup for extra-thoracic metastases and invasive staging of the mediastinum...
August 4, 2017: Oncologist
https://www.readbyqxmd.com/read/28778959/exceptional-response-with-immunotherapy-in-a-patient-with-anaplastic-thyroid-cancer
#9
Revathi Kollipara, Bryan Schneider, Milan Radovich, Sunil Babu, Patrick J Kiel
Chemotherapy with or without radiation is the standard therapy for anaplastic thyroid cancer (ATC), although the response rate is not high and not durable. We describe a 52-year-old male who was diagnosed with ATC and initially treated with a thyroidectomy and lymph node dissection, followed by chemotherapy. Next generation sequencing was then performed to guide therapy and the tumor was found to have BRAF and programmed death-ligand 1 (PD-L1) positivity that was subsequently treated with vemurafenib and nivolumab...
August 4, 2017: Oncologist
https://www.readbyqxmd.com/read/28778958/cell-free-dna-in-metastatic-colorectal-cancer-a-systematic-review-and-meta-analysis
#10
REVIEW
Karen-Lise G Spindler, Anders K Boysen, Niels Pallisgård, Julia S Johansen, Josep Tabernero, Morten M Sørensen, Benny V Jensen, Torben F Hansen, David Sefrioui, Rikke F Andersen, Ivan Brandslund, Anders Jakobsen
BACKGROUND: Circulating DNA can be detected and quantified in the blood of cancer patients and used for detection of tumor-specific genetic alterations. The clinical utility has been intensively investigated for the past 10 years. The majority of reports focus on analyzing the clinical potential of tumor-specific mutations, whereas the use of total cell-free DNA (cfDNA) quantification is somehow controversial and sparsely described in the literature, but holds important clinical information in itself...
August 4, 2017: Oncologist
https://www.readbyqxmd.com/read/28765503/advance-directives-hospitalization-and-survival-among-advanced-cancer-patients-with-delirium-presenting-to-the-emergency-department-a-prospective-study
#11
Ahmed F Elsayem, Eduardo Bruera, Alan Valentine, Carla L Warneke, Geri L Wood, Sai-Ching J Yeung, Valda D Page, Julio Silvestre, Patricia A Brock, Knox H Todd
BACKGROUND: To improve the management of advanced cancer patients with delirium in an emergency department (ED) setting, we compared outcomes between patients with delirium positively diagnosed by both the Confusion Assessment Method (CAM) and Memorial Delirium Assessment Scale (MDAS), or group A (n = 22); by the MDAS only, or group B (n = 22); and by neither CAM nor MDAS, or group C (n = 199). MATERIALS AND METHODS: In an oncologic ED, we assessed 243 randomly selected advanced cancer patients for delirium using the CAM and the MDAS and for presence of advance directives...
August 1, 2017: Oncologist
https://www.readbyqxmd.com/read/28765502/a-phase-ii-study-with-lead-in-safety-cohort-of-5-fluorouracil-oxaliplatin-and-lapatinib-in-combination-with-radiation-therapy-as-neoadjuvant-treatment-for-patients-with-localized-her2-positive-esophagogastric-adenocarcinomas
#12
Gregg Shepard, Edward R Arrowsmith, Patrick Murphy, John H Barton, James D Peyton, Mark Mainwaring, Laura Blakely, Noel A Maun, Johanna C Bendell
LESSONS LEARNED: Neoadjuvant 5-fluorouracil, oxaliplatin, and lapatinib in combination with radiation therapy is safe for neoadjuvant treatment for patients with localized human epidermal growth receptor 2-positive esophagogastric adenocarcinoma.Evaluation of this drug combination in a larger patient pool would allow for more accurate analysis of its efficacy. BACKGROUND: The optimal design of neoadjuvant chemoradiation for the treatment of localized esophagogastric cancers is the subject of much debate...
August 1, 2017: Oncologist
https://www.readbyqxmd.com/read/28754722/fixed-dosing-of-monoclonal-antibodies-in-oncology
#13
REVIEW
Jeroen J M A Hendrikx, John B A G Haanen, Emile E Voest, Jan H M Schellens, Alwin D R Huitema, Jos H Beijnen
Most monoclonal antibodies in oncology are administered in body-size-based dosing schedules. This is believed to correct for variability in both drug distribution and elimination between patients. However, monoclonal antibodies typically distribute to the blood plasma and extracellular fluids only, which increase less than proportionally with the increase in body weight. Elimination takes place via proteolytic catabolism, a nonspecific immunoglobulin G elimination pathway, and intracellular degradation after binding to the target...
July 28, 2017: Oncologist
https://www.readbyqxmd.com/read/28754721/activity-of-pazopanib-and-trabectedin-in-advanced-alveolar-soft-part-sarcoma
#14
Silvia Stacchiotti, Olivier Mir, Axel Le Cesne, Bruno Vincenzi, Alexander Fedenko, Robert G Maki, Neeta Somaiah, Shreyaskumar Patel, Mehedi Brahmi, Jean Y Blay, Kjetil Boye, Kirsten Sundby Hall, Hans Gelderblom, Nadia Hindi, Javier Martin-Broto, Hanna Kosela, Piotr Rutkowski, Antoine Italiano, Florence Duffaud, Eisuke Kobayashi, Paolo G Casali, Salvatore Provenzano, Akira Kawai
BACKGROUND: Alveolar soft part sarcoma (ASPS) is an exceedingly rare and orphan disease, without active drugs approved in the front line. Pazopanib and trabectedin are licensed for sarcoma treatment from second-line, but very little and contradictory data are available on their activity in ASPS. Lacking ongoing and/or planned clinical trials, we conducted a multi-institutional study involving the reference sites for sarcoma in Europe, U.S., and Japan, within the World Sarcoma Network, to investigate the efficacy of pazopanib and trabectedin...
July 28, 2017: Oncologist
https://www.readbyqxmd.com/read/28754720/tert-promoter-hypermethylation-in-gastrointestinal-cancer-a-potential-stool-biomarker
#15
Li Liu, Cheng Liu, Omid Fotouhi, Yidong Fan, Kun Wang, Chuanyou Xia, Benkang Shi, Guangyong Zhang, Kexin Wang, Feng Kong, Catharina Larsson, Sanyuan Hu, Dawei Xu
BACKGROUND: There is a high demand for noninvasive screening tools for gastrointestinal cancer (GIC) detection, and GIC-specific markers are required for such purposes. It is established that induction of the telomerase reverse transcriptase gene (TERT) coupled with telomerase activation is essential for cancer development/progression and aberrant TERT promoter methylation of specific 5'-C-phosphate-G-3' (CpGs) has been linked to TERT induction in oncogenesis. Here we analyzed TERT promoter methylation in fecal samples from GIC patients and healthy adults and determined its value as a stool biomarker for GIC detection...
July 28, 2017: Oncologist
https://www.readbyqxmd.com/read/28751507/commentary-on-weekly-low-dose-versus-three-weekly-high-dose-cisplatin-for-concurrent-chemoradiation-in-locoregionally-advanced-non-nasopharyngeal-head-and-neck-cancer-a-systematic-review-and-meta-analysis-of-aggregate-data
#16
https://www.readbyqxmd.com/read/28739869/the-harm-in-kratom
#17
LETTER
Joshua Z Drago, Bennett Lane, Jonathan Kochav, Bruce Chabner
No abstract text is available yet for this article.
July 24, 2017: Oncologist
https://www.readbyqxmd.com/read/28739868/what-s-the-harm
#18
Don S Dizon
No abstract text is available yet for this article.
July 24, 2017: Oncologist
https://www.readbyqxmd.com/read/28710342/vincristine-ifosfamide-and-doxorubicin-for-initial-treatment-of-ewing-sarcoma-in-adults
#19
Michael J Wagner, Vancheswaran Gopalakrishnan, Vinod Ravi, J Andrew Livingston, Anthony P Conley, Dejka Araujo, Neeta Somaiah, Maria A Zarzour, Ravin Ratan, Wei-Lien Wang, Shreyaskumar R Patel, Alexander Lazar, Joseph A Ludwig, Robert S Benjamin
BACKGROUND: There are no clinical trials specifically addressing chemotherapy for adults with Ewing sarcoma (ES). Five-year event-free survival (EFS) of adults on pediatric studies of ES (44%-47%) is worse than that of children treated with the same therapy (69%). The object of this study was to review the results of therapy with vincristine, ifosfamide, and doxorubicin (VID) in the multidisciplinary treatment of adults with ES at our institution. MATERIALS AND METHODS: Charts for adults treated for ES from 1995 to 2011 were retrospectively reviewed...
July 14, 2017: Oncologist
https://www.readbyqxmd.com/read/28706010/clinical-management-of-potential-toxicities-and-drug-interactions-related-to-cyclin-dependent-kinase-4-6-inhibitors-in-breast-cancer-practical-considerations-and-recommendations
#20
REVIEW
Laura M Spring, Mark L Zangardi, Beverly Moy, Aditya Bardia
Aberrations of the cell cycle are pervasive in cancer, and selective cell cycle inhibition of cancer cells is a target of choice for a number of novel cancer therapeutics. Cyclin-dependent kinases (CDKs) are key regulatory enzymes that control cell cycle transitions and the commitment to cell division. Palbociclib and ribociclib are both orally active, highly selective reversible inhibitors of CDK4 and CDK6 that are approved by the U.S. Food and Drug Administration (FDA) for hormone receptor-positive metastatic breast cancer in combination with specific endocrine therapies...
July 13, 2017: Oncologist
journal
journal
20207
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"